Slim Body Blog

Palatin Technologies,
Generic cialis pills no prescription Inc. (Amex: PTN) announced that dosing has been initiated in a Phase
2a clinical study of PL-3994, a novel, long-acting natriuretic peptide
receptor A agonist, in subjects with controlled hypertension.
The study is placebo-controlled and double-blinded, and will include up
to five cohorts receiving escalating doses. As many as 35 subjects will be
included, with six active subjects and one placebo subject per dose cohort.
Subjects passing screening are admitted to a research clinic, placed on a
controlled diet and have baseline blood pressures and laboratory values
monitored for 24 hours. The next morning, subjects receive a single dose of
PL-3994 or placebo with blood pressures and laboratory values monitored for
24 hours. Every other week, another cohort of subjects will receive a
higher dose of PL-3994 until a pre-specified blood pressure decrease is
observed.
"We are excited with our PL-3994 program’s rapid progress. Data from
these hypertensive patients will provide key indications of the compound’s
therapeutic potential," stated Dr. Trevor Hallam, Palatin’s Executive Vice
President for Research and Development. "We look forward to the completion
of this study as well as the reporting of results next quarter."
Based on the results of this study and the previously completed Phase 1
trial in healthy, non-hypertensive volunteers, a Phase 2 trial in patients
with episodes of hypertensive urgency is planned for later this calendar
year. Palatin is also developing PL-3994 for the treatment of acute
decompensated congestive heart failure and plans to initiate a separate
Phase 2 study in these patients later this calendar year.
About Acute Systemic Hypertension
An acute elevation of blood pressure, or acute hypertension, is a
life-threatening condition that can cause permanent damage to the brain,
heart, kidneys and blood vessels. It occurs in nearly 50 percent of
patients presenting to the hospital with acute heart failure and is a
common occurrence for patients with renal dysfunction. It is critical to
rapidly manage and maintain optimal blood pressure to minimize risk of
death and damage to vital organs. Of the over 35 million people in the
United States with hypertension, over one million people each year will
have one or more acute episodes of high blood pressure, requiring treatment
in an acute care setting.
About Congestive Heart Failure (CHF)
Currently in the U.S., CHF affects nearly 5 million people with 550,000
new cases of CHF diagnosed each year. Despite the treatment of CHF with
multiple drugs, almost all CHF patients will experience at least one
episode of acute CHF that requires treatment with intravenous medications
in the hospital. There were over 1,100,000 hospitalizations for CHF in
2004. Congestive heart failure has tremendous human and financial costs.
Estimated direct costs in the U.S. for CHF were $29.6 billion in 2006.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company primarily
focused on discovering and developing targeted, receptor-specific peptide
and small molecule therapeutics, including melanocortin ("MC")-based
therapeutics. Therapeutics affecting the activity of the MC family of
receptors may have the potential to treat a variety of conditions and
diseases, including sexual dysfunction, obesity and related disorders,
cachexia, hemorrhagic shock and inflammation-related diseases. The Company
is exploring other receptor-specific therapeutics, including natriuretic
peptide receptor A ("NPRA") agonist compounds for use in treatment of acute
systemic hypertension, congestive heart failure and other diseases.
Palatin’s strategy is to develop products and then form marketing
collaborations with industry leaders in order to maximize their commercial
potential. The Company currently has collaborations with AstraZeneca and
the Mallinckrodt division of Covidien. For additional information regarding
Palatin, please visit Palatin Technologies’ website at

Forward looking Statements
Statements about the Company’s future expectations, including
statements about its development programs, proposed indications for its
product candidates, pre-clinical activities, marketing collaborations, and
all other statements in this document other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934
and as that term is defined in the Private Securities Litigation Reform Act
of 1995. The Company intends that such forward-looking statements shall be
subject to the safe harbors created thereby. Palatin’s actual results may
differ materially from those discussed in the forward-looking statements
for various reasons, including, but not limited to the Company’s ability to
fund development of its technology, ability to establish and successfully
complete clinical trials and pre-clinical studies and the results of those
trials and studies, dependence on its partners for certain development
activities, need for regulatory approvals and commercial acceptance of its
products, ability to recommence marketing and gain commercial acceptance of
NeutroSpec(R), ability to protect its intellectual property, and other
factors discussed in the Company’s periodic filings with the Securities and
Exchange Commission. The Company is not responsible for updating for events
that occur after the date of this press release.
Palatin Technologies, Inc.

Buy levitra pills | Buy generic zithromax | Buy fosamax without prescription